Hospital CUF Porto S.A. — Clinical Trial Site

39 Registered trials

21 Currently recruiting

Organisation

Hospital CUF Porto S.A.

Location

Porto, Portugal

Identifier

ORG-100041883

Address

Estrada Da Circunvalacao N 14341, 4100-180, Portugal

Departments

#2101: Serviço de Imunoalergologia
3404:Serviço de Oncologia
5001:Serviço de Oncologia
5802: Pneumologia
Allergology
Medical Oncology
N/A
NA
Neuropsychiatry
Oncology
Oncology Department
Pneumology Service
Service of Oncology
Serviço de Oncologia
Serviço Pneumologia
Unidade de Ensaios Clínicos

Clinical trials at this site (39)

Search interface

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer Ended

2024-512998-27-00 Non-Small Cell Lung Cancer 5 2025-02-21
Study Comparing Tarlatamab and Durvalumab versus Durvalumab Alone in First Line ES-SCLC Following Platinum, Etoposide and Durvalumab (DeLLph… Ended

2023-505989-29-00 Extensive stage small cell lung cancer (ES-SCLC) 5 2024-11-21
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N… Ended

2022-500802-16-00 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
STEP Young: A research study on how well semaglutide helps children and teenagers with excess body weight lose weight Ended

2022-502922-41-00 Obesity and overweight 5 2023-07-03
A study to learn more about how well elinzanetant works and how safe it is compared to placebo for the treatment of hot flashes caused by an… Ended

2023-508265-33-00 Vasomotor symptoms caused by adjuvant endocrine therapy 5 2022-10-13
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended

2023-507933-12-00 Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
A research study on how well liraglutide works in children with obesity Ended

2023-508504-38-00 Obesity 5 2021-03-01
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Locally advanced or metastatic KRAS G12C-mutated non-sm 4 2022-12-06
Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102) Ended

2023-505458-16-00 Gastric and Gastroesophageal Junction Cancer With FGFR2 5 2022-09-13
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel… Ended

2022-502480-38-00 Non−small cell lung cancer (NSCLC) 5 2020-09-09
Pembrolizumab with Lenvatinib versus Docetaxel for Metastatic NSCLC after Platinum Doublet Chemotherapy and Immunotherapy Ended

2022-501439-18-00 NSCLC with squamous or nonsquamous histology 5 2019-06-26